The purpose of the study is to assess how safe the new injection is and how it changes the activity of a clotting protein called factor XI (FXI) over a 16‑week period. Participants will be randomly assigned to receive one of two hidden doses of the injection or the placebo, and all will receive the open‑label tablet. Visits will include simple blood draws to measure FXI activity and routine safety checks such as checking for bleeding or other side effects.

Throughout the trial, researchers will watch for any bleeding events, record any adverse experiences, and perform standard laboratory tests and vital‑sign measurements. Blood samples will also be taken at several time points to see how the drug behaves in the body and whether the immune system produces any antibodies against it.

The aim of the trial is to see whether adding the experimental drug reduces the chance of a large and lasting drop in kidney function, the development of end-stage kidney disease (very low kidney function requiring dialysis or transplant), or death from any cause. Participants will be randomly assigned to receive either the study drug or placebo, will take the assigned tablet each day, and will be monitored with regular clinic visits, blood tests, and urine checks over several years to record any health events.

After enrollment, participants will start the assigned medication within three days of the brain bleed and will continue taking it for several months. Throughout the study, they will have regular check‑ins to monitor health, including assessments of disability using the modified Rankin Scale, cognitive function with the Montreal Cognitive Assessment, and overall quality of life via the EQ-5D-5L questionnaire. The study will track any new strokes, heart attacks, or procedures to restore blood flow, as well as survival and the level of dependence on others at six months.

Participants in the study will receive either the medications or a placebo. The study will monitor changes in heart function using a test called echocardiography, which uses sound waves to create images of the heart. The study will also measure specific blood markers that indicate heart health. These assessments will help determine the impact of the medications on heart recovery after a heart attack.

The study will take place over a period of time, with participants being monitored at various intervals. The main focus will be on heart function and recovery within the first week after treatment, with additional follow-ups to assess longer-term effects. This research aims to provide valuable insights into the best timing and combination of these medications for improving outcomes in patients with STEMI.

The purpose of the study is to see whether treatment with zodasiran can reduce LDL‑C in teenage participants aged 12 to under 18 years. Over about a year, participants receive regular injections and have blood drawn at scheduled visits to check changes in LDL‑C as well as other blood substances such as Apolipoprotein B (a protein that carries cholesterol), non‑HDL‑C (all cholesterol that is not the “good” HDL), Triglycerides (a type of fat in the blood), Angiopoietin‑like Protein 3 (a protein that can affect cholesterol levels), and HDL‑C (high‑density lipoprotein cholesterol, often called “good” cholesterol). The trial is open‑label, meaning both doctors and participants know the medication being used, and there is no comparison group.

The purpose of the study is to determine whether adding ALXN2220 to eplontersen improves the ability to exercise compared with eplontersen plus placebo. To assess this, participants will perform a cardiopulmonary exercise test (CPET), a breathing and exercise test that measures the maximum amount of oxygen the body can use during intense activity. The test will be done at the start of the study and again after about a year of treatment.

During the trial, participants will visit the clinic regularly for the subcutaneous injections, the intravenous infusions, and safety checks such as blood tests and heart examinations. The study will continue for roughly 52 weeks, with scheduled appointments to monitor how the heart is working and to record any side effects. All procedures are designed to follow standard safety guidelines.